Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Switch from intravenous to enteral moxifloxacin in critically ill patients: a pilot study.

de Smet J, Colpaert K, de Paepe P, van Bocxlaer J, Decruyenaere J, Boussery K.

Scand J Infect Dis. 2012 Nov;44(11):874-8. doi: 10.3109/00365548.2012.693194. Epub 2012 Jul 17.

PMID:
22804100
2.

Population pharmacokinetics and pharmacodynamic evaluation of intravenous and enteral moxifloxacin in surgical intensive care unit patients.

Kees MG, Schaeftlein A, Haeberle HA, Kees F, Kloft C, Heininger A.

J Antimicrob Chemother. 2013 Jun;68(6):1331-7. doi: 10.1093/jac/dkt040. Epub 2013 Mar 5.

3.

Effects of enteral feeding on the oral bioavailability of moxifloxacin in healthy volunteers.

Burkhardt O, Stass H, Thuss U, Borner K, Welte T.

Clin Pharmacokinet. 2005;44(9):969-76.

PMID:
16122283
4.

Oral bioavailability of moxifloxacin after Roux-en-Y gastric bypass surgery.

De Smet J, Colin P, De Paepe P, Ruige J, Batens H, Van Nieuwenhove Y, Vogelaers D, Blot S, Van Bocxlaer J, Van Bortel LM, Boussery K.

J Antimicrob Chemother. 2012 Jan;67(1):226-9. doi: 10.1093/jac/dkr436. Epub 2011 Oct 10.

5.

Disposition kinetics of moxifloxacin in lactating ewes.

Goudah A.

Vet J. 2008 Nov;178(2):282-7. Epub 2007 Sep 27.

PMID:
17900948
6.

Pharmacokinetics of moxifloxacin in patients with severe sepsis or septic shock.

Pletz MW, Bloos F, Burkhardt O, Brunkhorst FM, Bode-Böger SM, Martens-Lobenhoffer J, Greer MW, Stass H, Welte T.

Intensive Care Med. 2010 Jun;36(6):979-83. doi: 10.1007/s00134-010-1864-y. Epub 2010 Mar 25.

PMID:
20336279
7.

Pharmacokinetics and pharmacodynamics of three moxifloxacin dosage forms: implications for blinding in active-controlled cardiac repolarization studies.

Mason JW, Florian JA Jr, Garnett CE, Moon TE, Selness DS, Spaulding RR.

J Clin Pharmacol. 2010 Nov;50(11):1249-59. doi: 10.1177/0091270009356298. Epub 2010 Feb 9.

PMID:
20145260
8.

Moxifloxacin penetration in bronchial secretions of mechanically ventilated patients with pneumonia.

Leone M, Albanèse J, Sampol-Manos E, Simon N, Lacarelle B, Bruguerolle B, Martin C.

Antimicrob Agents Chemother. 2004 Feb;48(2):638-40.

9.

Conjunctival concentrations of a new ophthalmic solution formulation of moxifloxacin 0.5% in cataract surgery patients.

Lindstrom R, Lane S, Cottingham A, Smith S, Sall K, Silverstein S, Shettle L, Walters T, Faulkner R, Cockrum P, Teuscher N.

J Ocul Pharmacol Ther. 2010 Dec;26(6):591-5. doi: 10.1089/jop.2010.0089. Epub 2010 Oct 6.

PMID:
20925517
10.

Bioavailability of gatifloxacin by gastric tube administration with and without concomitant enteral feeding in critically ill patients.

Kanji S, McKinnon PS, Barletta JF, Kruse JA, Devlin JW.

Crit Care Med. 2003 May;31(5):1347-52.

PMID:
12771601
11.

Pharmacokinetics and bioavailability of moxifloxacin in buffalo calves.

Pathania R, Sharma SK.

Res Vet Sci. 2010 Aug;89(1):108-12. doi: 10.1016/j.rvsc.2010.01.015. Epub 2010 Mar 3.

PMID:
20202656
12.

Efficacy and safety of moxifloxacin for community-acquired bacterial pneumonia based on pharmacokinetic analysis.

Yoshida K, Okimoto N, Kishimoto M, Fukano H, Hara H, Yoneyama H, Moriya O, Kawanishi M, Kimura M, Matsushima T, Niki Y.

J Infect Chemother. 2011 Oct;17(5):678-85. doi: 10.1007/s10156-011-0282-6. Epub 2011 Aug 17.

PMID:
21847518
13.

Penetration of moxifloxacin into the human pancreas following a single intravenous or oral dose.

Wacke R, Förster S, Adam U, Mundkowski RG, Klar E, Hopt UT, Drewelow B.

J Antimicrob Chemother. 2006 Nov;58(5):994-9. Epub 2006 Sep 6.

14.

Pharmacokinetics and tissue penetration of moxifloxacin in intervention therapy for intra-abdominal abscess.

Rink AD, Stass H, Delesen H, Kubitza D, Vestweber KH.

Clin Drug Investig. 2008;28(2):71-9.

PMID:
18211115
15.

Pharmacokinetic variables of moxifloxacin in healthy male camels following intravenous and intramuscular administration.

Abd El-Aty AM, Goudah A, Shah SS, Shin HC, Shimoda M, Shim JH.

J Vet Pharmacol Ther. 2007 Dec;30(6):586-91. No abstract available.

PMID:
17991229
16.

Pharmacokinetics of moxifloxacin in patients undergoing continuous ambulatory peritoneal dialysis.

Skalioti C, Tsaganos T, Stamatiadis D, Giamarellos-Bourboulis EJ, Boletis J, Kanellakopoulou K.

Perit Dial Int. 2009 Sep-Oct;29(5):575-9.

17.

Pharmacokinetics of moxifloxacin in plasma and tissue of morbidly obese patients.

Kees MG, Weber S, Kees F, Horbach T.

J Antimicrob Chemother. 2011 Oct;66(10):2330-5. doi: 10.1093/jac/dkr282. Epub 2011 Jul 5.

18.

Differential aqueous and vitreous concentrations of moxifloxacin and ofloxacin after topical administration one hour before vitrectomy.

Lai WW, Chu KO, Chan KP, Choy KW, Wang CC, Tsang CW, Pang CP.

Am J Ophthalmol. 2007 Aug;144(2):315-8.

PMID:
17659971
20.

Pharmacokinetics and peritoneal penetration of moxifloxacin in peritonitis.

Stass H, Rink AD, Delesen H, Kubitza D, Vestweber KH.

J Antimicrob Chemother. 2006 Sep;58(3):693-6.

Items per page

Supplemental Content

Write to the Help Desk